Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor
Jaclyn J. Renfrow(Atrium Health Wake Forest Baptist), Roy E. Strowd(Wake Forest University), Jann N. Sarkaria(Mayo Clinic in Arizona), Shakti Ramkissoon(Foundation Medicine (United States)), Stephanie Sanders(Atrium Health Wake Forest Baptist), Ralph B. D’Agostino(Wake Forest University), Mark B. Frenkel(Atrium Health Wake Forest Baptist), James L. W. West(Twin Cities Orthopedics), Carol Kittel(Atrium Health Wake Forest Baptist), Adrian W. Laxton(Atrium Health Wake Forest Baptist), Ryan T. Mott(Atrium Health Wake Forest Baptist), Waldemar Debinski(Wake Forest University), Stephen B. Tatter(Atrium Health Wake Forest Baptist), Linda J. Metheny‐Barlow(Wake Forest University), Denise Herpai(Atrium Health Wake Forest Baptist), M. Soike(Atrium Health Wake Forest Baptist), Gregory A. Hawkins(Wake Forest University), Glenn J. Lesser(Virginia Commonwealth University)
Cited by 54
Related Papers
Prediction of Coronary Heart Disease Using Risk Factor Categories
|Circulation|1998|9.6k
General Cardiovascular Risk Profile for Use in Primary Care
|Circulation|2008|7.4k
Impact of Atrial Fibrillation on the Risk of Death
|Circulation|1998|4.6k
Abdominal Visceral and Subcutaneous Adipose Tissue Compartments
|Circulation|2007|2.9k
A Controlled Trial of Renal Denervation for Resistant Hypertension
|New England Journal of Medicine|2014|2.2k